KNSA — Kiniksa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.27bn
- $1.06bn
- $270.26m
- 76
- 13
- 90
- 62
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -162 | -161 | -158 | 183 | 14.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 21.6 | 22.4 | 28.6 | 28.1 | 29.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -17 | -4.32 | 0.689 | -22.6 | 1.35 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -158 | -137 | -126 | 5.81 | 13.3 |
Capital Expenditures | -3.2 | -0.283 | -20.4 | -0.105 | -0.13 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 52.4 | -23.2 | 149 | -7.97 | -29.4 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 49.2 | -23.4 | 129 | -8.08 | -29.6 |
Financing Cash Flow Items | -0.118 | -1.14 | — | -0.901 | -2.21 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 84.1 | 227 | 5.88 | 2.52 | 1.5 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -25 | 67.1 | 8.22 | 0.245 | -14.8 |